1
4
↑1
↓4
—0
Evidence suggests Psilocybin maydecreaseStress arousal.
4 studies (5 claims)
Emerging evidence
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA | Increases - has shown promise | conditions including depression and post-traumatic stress disorder | Human | — | Not mentioned | Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.cited 1× |
| psilocybin | Decreases - reported positive outcomes | depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders | Human | — | Not specified | Licit use of illicit drugs for treating depression: the pill and the process. |
| psilocybin | Decreases - significantly reduced | stress-induced behavioral despair | Animal | male Wistar rats | Not specified | Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats.cited 1× |
| psilocybin | Decreases - has sustained beneficial effects | stress-related behavioral disturbances | Animal | male Wistar rats | Not specified | Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats.cited 1× |
| psilocybin | Decreases - has sustained beneficial effects | stress-related cognitive disturbances | Animal | male Wistar rats | Not specified | Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats.cited 1× |
| psilocybin | No effect - investigated | therapeutic effect on post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) | Human | — | Not mentioned | Registered clinical studies investigating psychedelic drugs for psychiatric disorders.cited 51× |